AU2017218768B2 - Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease - Google Patents

Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease Download PDF

Info

Publication number
AU2017218768B2
AU2017218768B2 AU2017218768A AU2017218768A AU2017218768B2 AU 2017218768 B2 AU2017218768 B2 AU 2017218768B2 AU 2017218768 A AU2017218768 A AU 2017218768A AU 2017218768 A AU2017218768 A AU 2017218768A AU 2017218768 B2 AU2017218768 B2 AU 2017218768B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
antibody
coa
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017218768A
Other languages
English (en)
Other versions
AU2017218768A1 (en
Inventor
Mark DE BEEN
Carla EMOLO
Jeroen GEURTSEN
Molly MCADOW
Dominique Missiakas
Olaf Schneewind
Lena THOMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Janssen Pharmaceuticals Inc
Original Assignee
University of Chicago
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Janssen Pharmaceuticals Inc filed Critical University of Chicago
Publication of AU2017218768A1 publication Critical patent/AU2017218768A1/en
Application granted granted Critical
Publication of AU2017218768B2 publication Critical patent/AU2017218768B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017218768A 2016-02-12 2017-02-10 Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease Ceased AU2017218768B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294413P 2016-02-12 2016-02-12
US62/294,413 2016-02-12
PCT/IB2017/050763 WO2017137954A2 (en) 2016-02-12 2017-02-10 Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Publications (2)

Publication Number Publication Date
AU2017218768A1 AU2017218768A1 (en) 2018-08-09
AU2017218768B2 true AU2017218768B2 (en) 2022-03-31

Family

ID=59563610

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017218768A Ceased AU2017218768B2 (en) 2016-02-12 2017-02-10 Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Country Status (5)

Country Link
US (2) US11214600B2 (enExample)
EP (1) EP3416979A4 (enExample)
JP (1) JP7117244B2 (enExample)
AU (1) AU2017218768B2 (enExample)
WO (1) WO2017137954A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EP2844275B1 (en) * 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
CN114062665B (zh) * 2020-08-05 2023-04-28 菲鹏生物股份有限公司 示踪粒子标记目标分子及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2015057893A2 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
US20150368322A1 (en) * 2012-04-26 2015-12-24 Molly Mcadow Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
DK1121135T3 (da) 1998-09-14 2009-03-23 Nabi Biopharmaceuticals Præparater af beta-glucaner og specifikke immunglobuliner
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
KR101541383B1 (ko) * 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
SMT202000246T1 (it) 2009-04-03 2020-07-08 Univ Chicago Composizioni e metodi relativi a varianti della proteina a (spa)
CA2758490C (en) * 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
US9085631B2 (en) * 2011-04-08 2015-07-21 Nov Vac APS Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US9353189B2 (en) * 2014-01-24 2016-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
US20150368322A1 (en) * 2012-04-26 2015-12-24 Molly Mcadow Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2015057893A2 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery

Also Published As

Publication number Publication date
JP2019514343A (ja) 2019-06-06
US20190112342A1 (en) 2019-04-18
WO2017137954A3 (en) 2017-09-28
EP3416979A4 (en) 2019-09-11
US11214600B2 (en) 2022-01-04
US20220227819A1 (en) 2022-07-21
WO2017137954A2 (en) 2017-08-17
EP3416979A2 (en) 2018-12-26
AU2017218768A1 (en) 2018-08-09
JP7117244B2 (ja) 2022-08-12

Similar Documents

Publication Publication Date Title
US11939358B2 (en) Compositions and methods related to protein A (SpA) variants
AU2010271116B2 (en) Compositions and methods related to Protein A (SpA) variants
US9095540B2 (en) Methods and compositions involving protective staphylococcal antigens
US20220227819A1 (en) Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2014179744A1 (en) Staphylococcus live cell vaccines
AU2013252883B2 (en) Staphylococcal coagulase antigens and methods of their use
JP7643730B2 (ja) ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物
AU2015202158B2 (en) Compositions and methods related to protein a (spa) variants

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired